{
     "PMID": "24887203",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20140925",
     "LR": "20161126",
     "IS": "0006-3002 (Print) 0006-3002 (Linking)",
     "VI": "1842",
     "IP": "9",
     "DP": "2014 Sep",
     "TI": "Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease.",
     "PG": "1556-66",
     "LID": "10.1016/j.bbadis.2014.05.025 [doi] S0925-4439(14)00153-7 [pii]",
     "AB": "The present study had focused on the behavioral phenotype and gene expression profile of molecules related to insulin receptor signaling in the hippocampus of 3 and 6 month-old APPswe/PS1dE9 (APP/PS1) transgenic mouse model of Alzheimer's disease (AD). Elevated levels of the insoluble Abeta (1-42) were detected in the brain extracts of the transgenic animals as early as 3 months of age, prior to the Abeta plaque formation (pre-plaque stage). By the early plaque stage (6 months) both the soluble and insoluble Abeta (1-40) and Abeta (1-42) peptides were detectable. We studied the expression of genes related to memory function (Arc, Fos), insulin signaling, including insulin receptor (Insr), Irs1 and Irs2, as well as genes involved in insulin growth factor pathways, such as Igf1, Igf2, Igfr and Igfbp2. We also examined the expression and protein levels of key molecules related to energy metabolism (PGC1-alpha, and AMPK) and mitochondrial functionality (OXPHOS, TFAM, NRF1 and NRF2). 6 month-old APP/PS1 mice demonstrated impaired cognitive ability, were glucose intolerant and showed a significant reduction in hippocampal Insr and Irs2 transcripts. Further observations also suggest alterations in key cellular energy sensors that regulate the activities of a number of metabolic enzymes through phosphorylation, such as a decrease in the Prkaa2 mRNA levels and in the pAMPK (Thr172)/Total APMK ratio. Moreover, mRNA and protein analysis reveals a significant downregulation of genes essential for mitochondrial replication and respiratory function, including PGC-1alpha in hippocampal extracts of APP/PS1 mice, compared to age-matched wild-type controls at 3 and 6 months of age. Overall, the findings of this study show early alterations in genes involved in insulin and energy metabolism pathways in an APP/PS1 model of AD. These changes affect the activity of key molecules like NRF1 and PGC-1alpha, which are involved in mitochondrial biogenesis. Our results reinforce the hypothesis that the impairments in both insulin signaling and energy metabolism precede the development of AD amyloidogenesis.",
     "CI": [
          "Copyright (c) 2014 Elsevier B.V. All rights reserved."
     ],
     "FAU": [
          "Pedros, Ignacio",
          "Petrov, Dmitry",
          "Allgaier, Michael",
          "Sureda, Francesc",
          "Barroso, Emma",
          "Beas-Zarate, Carlos",
          "Auladell, Carme",
          "Pallas, Merce",
          "Vazquez-Carrera, Manuel",
          "Casadesus, Gemma",
          "Folch, Jaume",
          "Camins, Antoni"
     ],
     "AU": [
          "Pedros I",
          "Petrov D",
          "Allgaier M",
          "Sureda F",
          "Barroso E",
          "Beas-Zarate C",
          "Auladell C",
          "Pallas M",
          "Vazquez-Carrera M",
          "Casadesus G",
          "Folch J",
          "Camins A"
     ],
     "AD": "Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia, Institut de Biomedicina de la UB (IBUB), Universitat de Barcelona, Barcelona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia, Institut de Biomedicina de la UB (IBUB), Universitat de Barcelona, Barcelona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia, Institut de Biomedicina de la UB (IBUB), Universitat de Barcelona, Barcelona, Spain; Centros de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Department of Neurosciences, Case Western Reserve University, Cleveland OH USA; Laboratorio de Neurobiologia Celular y Molecular, Division de Neurociencias, CIBO, IMSS, Mexico; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Departament de Biologia Cellular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia, Institut de Biomedicina de la UB (IBUB), Universitat de Barcelona, Barcelona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia, Institut de Biomedicina de la UB (IBUB), Universitat de Barcelona, Barcelona, Spain; Centros de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Department of Neurosciences, Case Western Reserve University, Cleveland OH USA; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitats de Bioquimica i Farmacologia, Facultat de Medicina i Ciencies de la Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia, Institut de Biomedicina de la UB (IBUB), Universitat de Barcelona, Barcelona, Spain; Centros de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Laboratorio de Regeneracion y Desarrollo Neural, Instituto de Neurobiologia, Departamento de Biologia Celular y Molecular, CUCBA, Mexico. Electronic address: camins@ub.edu.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20140602",
     "PL": "Netherlands",
     "TA": "Biochim Biophys Acta",
     "JT": "Biochimica et biophysica acta",
     "JID": "0217513",
     "RN": [
          "0 (APP protein, human)",
          "0 (Amyloid beta-Protein Precursor)",
          "0 (Amyloidogenic Proteins)",
          "0 (Biomarkers)",
          "0 (Presenilin-1)",
          "0 (RNA, Messenger)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/genetics/*metabolism/pathology",
          "Amyloid beta-Protein Precursor/*physiology",
          "Amyloidogenic Proteins",
          "Animals",
          "Biomarkers/metabolism",
          "Blotting, Western",
          "*Disease Models, Animal",
          "*Energy Metabolism",
          "Enzyme-Linked Immunosorbent Assay",
          "Hippocampus/*metabolism/pathology",
          "Immunoenzyme Techniques",
          "Male",
          "Mice",
          "Mice, Inbred C57BL",
          "Mice, Transgenic",
          "Mitochondria/*metabolism/pathology",
          "Presenilin-1/*physiology",
          "RNA, Messenger/genetics",
          "Real-Time Polymerase Chain Reaction",
          "Reverse Transcriptase Polymerase Chain Reaction"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "APPswe/PS1dE9",
          "Alzheimer's disease",
          "Hippocampus",
          "Insulin receptor",
          "Mitochondria",
          "Tau"
     ],
     "EDAT": "2014/06/03 06:00",
     "MHDA": "2014/09/26 06:00",
     "CRDT": [
          "2014/06/03 06:00"
     ],
     "PHST": [
          "2014/02/07 00:00 [received]",
          "2014/05/12 00:00 [revised]",
          "2014/05/20 00:00 [accepted]",
          "2014/06/03 06:00 [entrez]",
          "2014/06/03 06:00 [pubmed]",
          "2014/09/26 06:00 [medline]"
     ],
     "AID": [
          "S0925-4439(14)00153-7 [pii]",
          "10.1016/j.bbadis.2014.05.025 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Biochim Biophys Acta. 2014 Sep;1842(9):1556-66. doi: 10.1016/j.bbadis.2014.05.025. Epub 2014 Jun 2.",
     "term": "hippocampus"
}